DOMAIN: CLINICAL BIOINFORMATICS & PRECISION ONCOLOGY
PIPELINE #079
Clinical Rare Disease Trio Exome/Genome ACMG/AMP Variant Prioritization
Technical Scope: Pedigree-aware inheritance modeling (de novo, compound heterozygous, autosomal recessive), phenotype-driven ranking (HPO), and ACMG pathogenicity scoring.
Required Input Data & Formats
Proband + Parents Joint VCF (.vcf.gz), PED Pedigree File (.ped), Patient Human Phenotype Ontology (HPO) Terms (.txt).
Produced Output Files & Deliverables
Prioritized Candidate Variant Report (.xlsx/.html), ACMG/AMP Evidence Criteria Breakdown (.tsv), Segregating De Novo & Recessive Variant List.
Core Software Toolchain & Frameworks
Exomiser, Slivar, InterVar / AutoPVS1, CADD / REVEL / SpliceAI, Ensembl VEP, Genomizer.
Key Literature & Methodological References
Smedley et al. (2015) Nature Protocols (Exomiser); Pedersen et al. (2021) Human Mutation (Slivar); Richards et al. (2015) Genetics in Medicine (ACMG Guidelines).
Application
“Finding a single causal mutation among four million variants in a rare disease patient requires combining Mendelian pedigree filtering with deep clinical phenotype matching. Our Clinical Rare Disease Trio pipeline integrates Slivar inheritance filtering with Exomiser—scoring variants by population rarity in gnomAD, in silico deleteriousness (REVEL, CADD, SpliceAI), and semantic similarity between patient HPO phenotypes and human/model-organism gene-disease associations—while automatically applying ACMG/AMP classification rules. Dramatically shorten the diagnostic odyssey for rare genetic disorders.”
DOMAIN: CLINICAL BIOINFORMATICS & PRECISION ONCOLOGY
PIPELINE #080
Molecular Tumor Board (MTB) Actionable Variant & Clinical Trial Matching
Technical Scope: Somatic SNV, CNV, and fusion integration with OncoKB, CIViC, and JAX-CKB to match patients with FDA/EMA targeted therapies and clinical trials.
Required Input Data & Formats
Somatic VCF (.vcf.gz), Segmented CNV (.seg), Fusion Calls (.tsv), Patient Tumor Type (OncoTree Code) & Clinical History.
Produced Output Files & Deliverables
Tiered AMP/ASCO/CAP Actionability Report (.pdf/.html), Matched Approved Therapies & Resistance Alerts (.tsv), Eligible Clinical Trials List.
Core Software Toolchain & Frameworks
Personal Cancer Genome Reporter (PCGR), OpenCRAVAT, OncoKB API, CIViCpy, VEP.
Key Literature & Methodological References
Nakken et al. (2018) Bioinformatics (PCGR); Chakravarty et al. (2017) JCO Precision Oncology (OncoKB); Li et al. (2017) Journal of Molecular Diagnostics (AMP/ASCO/CAP).
Application
“Translating complex comprehensive genomic profiling panels into clear treatment decisions requires mapping multi-modal alterations against rapidly evolving precision oncology knowledgebases. Our Molecular Tumor Board pipeline integrates somatic mutations, copy-number amplifications, and gene fusions through PCGR and OpenCRAVAT, annotating every alteration against OncoKB and CIViC using AMP/ASCO/CAP evidence tiers. We highlight sensitizing biomarkers, resistance mechanisms, and active biomarker-driven clinical trials—empowering oncology teams with clear, evidence-graded clinical reports.”
DOMAIN: CLINICAL BIOINFORMATICS & PRECISION ONCOLOGY
PIPELINE #081
Homologous Recombination Deficiency (HRD) & Genomic Scar Scoring
Technical Scope: Allele-specific copy number segmentation to compute LOH, Telomeric Allelic Imbalance (TAI), Large-Scale State Transitions (LST), and HRD sum score.
Required Input Data & Formats
Tumor & Matched Normal WGS/WES BAM (.bam), Common SNP Pileup Counts (.tsv), Reference Genome (.fasta).
Produced Output Files & Deliverables
Allele-Specific Copy Number & Purity/Ploidy Profile (.pdf), HRD Score Breakdown (LOH + TAI + LST, .tsv), BRCA1/2 & HRR Pathway Mutation Status.
Core Software Toolchain & Frameworks
Sequenza, ASCAT, scarHRD, HRDetect, CHORD, Purple (Hartwig).
Key Literature & Methodological References
Sztupinszki et al. (2018) npj Breast Cancer (scarHRD); Davies et al. (2017) Nature Medicine (HRDetect); Favero et al. (2015) Annals of Oncology (Sequenza).
Application
“Patients with Homologous Recombination Deficiency benefit profoundly from PARP inhibitors and platinum chemotherapy—even in the absence of germline BRCA1/2 mutations. Our HRD and Genomic Scar Scoring pipeline reconstructs tumor purity, ploidy, and allele-specific copy number using Sequenza and ASCAT, then computes Loss of Heterozygosity, Telomeric Allelic Imbalance, and Large-Scale State Transitions via scarHRD alongside mutational signature-based HRDetect scoring. Identify PARP-inhibitor-sensitive patients across ovarian, breast, prostate, and pancreatic oncology cohorts.”
DOMAIN: CLINICAL BIOINFORMATICS & PRECISION ONCOLOGY
PIPELINE #082
HLA Class I/II High-Resolution Typing & Loss of Heterozygosity (HLA-LOH) Analysis
Technical Scope: 4-field classical and non-classical HLA genotyping from WGS/WES/RNA-Seq and somatic allele-specific HLA loss detection in tumors.
Required Input Data & Formats
Tumor & Matched Normal WGS/WES or RNA-Seq FASTQ/BAM (.fastq.gz/.bam).
Produced Output Files & Deliverables
4-Field HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 Genotypes (.tsv), Somatic HLA Allele-Specific Copy Number & LOH Calls (.tsv/.pdf).
Core Software Toolchain & Frameworks
OptiType, HLA-HD, ArcasHLA (RNA-Seq), LOHHLA, SpecHLA.
Key Literature & Methodological References
Szolek et al. (2014) Bioinformatics (OptiType); McGranahan et al. (2017) Cell (LOHHLA); Kawaguchi et al. (2017) Human Mutation (HLA-HD).
Application
“Tumors frequently evade T-cell recognition and checkpoint blockade by selectively deleting the specific HLA class I allele presenting immunogenic neoantigens—an immune escape mechanism missed by standard copy number callers due to extreme polymorphism in the MHC locus. Our HLA Typing and HLA-LOH pipeline combines OptiType and HLA-HD for 4-field germline genotyping with LOHHLA allele-specific alignment to detect focal somatic HLA loss. Essential for immuno-oncology biomarker stratification and neoantigen vaccine design, ensuring you never target an HLA allele the tumor has already deleted.”
DOMAIN: CLINICAL BIOINFORMATICS & PRECISION ONCOLOGY
PIPELINE #083
Tumor Evolutionary Phylogeny & Subclonal Reconstruction (WGS/Multi-Region)
Technical Scope: Cancer Cell Fraction (CCF) estimation, subclonal clustering, and reconstruction of branched evolutionary trees across primary and metastatic biopsies.
Required Input Data & Formats
Somatic SNV/Indel VCFs (.vcf.gz) & Allele-Specific Copy Number Calls (.tsv) across 1+ Tumor Samples per Patient.
Produced Output Files & Deliverables
Cancer Cell Fraction (CCF) & Clone Assignment Table (.tsv), Fishplots & Phylogenetic Clone Trees (.pdf/.svg), Truncal vs. Branch Driver Classification.
Core Software Toolchain & Frameworks
PyClone-VI, PhyloWGS, Clonality / SciClone, Treeomics, Timescape / Fishplot.
Key Literature & Methodological References
Gillis & Roth (2020) BMC Bioinformatics (PyClone-VI); Deshwar et al. (2015) Genome Biology (PhyloWGS); Reiter et al. (2017) Nature Communications (Treeomics).
Application
“Targeting a subclonal mutation present in only 20% of tumor cells guarantees rapid therapeutic resistance. Distinguishing early truncal founder mutations from late branch alterations requires jointly modeling variant allele frequencies, local copy number, and tumor purity. Our Tumor Evolutionary Phylogeny pipeline uses PyClone-VI and Treeomics to infer Cancer Cell Fractions across single or multi-region longitudinal biopsies, reconstructing branched evolutionary trees and clonal fishplots—guiding combination therapy strategies and truncal target selection.”
DOMAIN: CLINICAL BIOINFORMATICS & PRECISION ONCOLOGY
PIPELINE #084
Clinical Data Standardization & Regulatory CDISC SDTM / OMOP CDM Mapping
Technical Scope: Semantic harmonization, controlled terminology mapping, and programmatic transformation of clinical/biomarker data into CDISC SDTM or OMOP CDM.
Required Input Data & Formats
Raw Clinical EDC Exports, Lab/Biomarker Tables (.csv/.sas7bdat/.xlsx), Data Dictionary & Study Protocol.
Produced Output Files & Deliverables
CDISC SDTM Domains (DM, LB, MB, PF, QS in .xpt/.parquet) or OMOP CDM Relational Tables, Define-XML & Pinnacle 21 Validation Report.
Core Software Toolchain & Frameworks
Python (pandas, pyreadstat), R (admiral, sdtm.oak, metacore), OHDSI WhiteRabbit / Usagi / Rabbit-in-a-Hat, Pinnacle 21.
Key Literature & Methodological References
CDISC SDTM Implementation Guide; OHDSI Book of Observational Health Data Sciences (OMOP CDM); PharmaVerse (admiral).
Application
“Fragmented clinical trial spreadsheets and incompatible hospital EHR schemas delay regulatory submissions and prevent federated multi-center biomarker discovery. Our Clinical Data Standardization pipeline transforms raw clinical, laboratory, and molecular biomarker datasets into fully compliant CDISC SDTM domains for FDA and EMA submissions, or OHDSI OMOP Common Data Models for real-world evidence federation. Complete with controlled terminology mapping, automated validation checks, and auditable provenance, we make your clinical and translational datasets submission- and AI-ready.”
DOMAIN: CLINICAL BIOINFORMATICS & PRECISION ONCOLOGY
PIPELINE #085
Cancer Molecular Subtyping & Prognostic Gene Signature Scoring
Technical Scope: Single-sample transcriptomic classification into validated molecular subtypes (e.g., PAM50, CMS colorectal, TCGA subtypes) and pathway risk scores.
Required Input Data & Formats
Normalized Tumor Gene Expression Matrix (TPM/FPKM/Counts, .tsv), Tumor Type Annotation (.csv).
Produced Output Files & Deliverables
Sample Molecular Subtype Assignments & Posterior Probabilities (.csv), Single-Sample Pathway & Immune Signature Scores (.tsv), Subtype Kaplan-Meier Survival Plots (.pdf).
Core Software Toolchain & Frameworks
genefu (PAM50), CMSclassifier, singscore, GSVA / ssGSEA, ConsensusTME, survival / survminer.
Key Literature & Methodological References
Gendoo et al. (2016) Bioinformatics (genefu); Guinney et al. (2015) Nature Medicine (CMS); Foroutan et al. (2018) BMC Bioinformatics (singscore).
Application
“Established transcriptomic molecular subtypes—such as PAM50 in breast cancer or Consensus Molecular Subtypes in colorectal cancer—carry profound prognostic and predictive value for clinical trial stratification. Our Cancer Molecular Subtyping pipeline applies rank-based, batch-resilient single-sample scoring via singscore and GSVA alongside validated classifiers like genefu and CMSclassifier, followed by Cox proportional hazards and Kaplan-Meier survival modeling. Rapidly stratify patient cohorts and benchmark novel biomarkers against established clinical molecular subtypes.”
Back to Workflows